Compare TG Therapeutics Inc (TGTX) vs Tesla, Inc. (TSLA) Price & Performance

TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.

The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.

Tesla (TSLA) trades at $380.84, down 2.64% amid bearish technical signals and mixed earnings performance. The stock faces pressure from declining profit margins (net margin 3.95% in 2025) and elevated valuations (P/E 339), though recent Q1 2026 EPS beat expectations. Technical analysis shows bearish momentum with key support at $371, while news highlights regulatory approvals for self-driving software in Europe and a strategic pivot toward AI and robotics.

Outlook remains cautious due to high valuation and competitive pressures, but long-term growth potential exists in autonomy and energy segments. Risks include execution challenges in new business lines and volatile cash flows. Analyst consensus price target is $409.26 with mixed ratings (38% Buy, 43% Hold).